For acquisition · Listed May 22, 2026 · Direct from owner

An exact-match keyword domain, a 90-page citation-grade content library, and a brand-safe position in a $9.86B market.

drugtest.co is for sale as a turnkey acquisition: the domain, the entire site, the editorial framework, the source build, and the brand position — assembled at replacement cost north of $70,000 and listed below at a price designed to move.

Asking price · Buy It Now

$24,500USD

Includes domain transfer, full content, source build, and brand assets. Escrow.com or Dan.com transfer supported. Reasonable offers above $19,500 will be considered.

Buy now via Escrow.com → See what's included

$9.86B

Global drug screening market size in 2026, projected to reach $20.86B by 2031 (15.5% CAGR).

Mordor Intelligence · MarketsandMarkets
90+

Indexed pages: test types, panels, substances, detection windows, glossary, guides, workplace, at-home.

Sitemap-index.xml
~56%

Of U.S. employers conduct drug testing — 71% at worksites with 1,000+ employees.

American Addiction Centers / NIAAA
EMD

Exact-match keyword domain on a premium TLD recognized for tech & startup brands.

Domain marketplace data

Executive summary

The thirty-second pitch

drugtest.co is a finished, editorially-defensible brand on a premium exact-match domain in a category dominated by gray-market competitors. It is sold "vacant" — without revenue, without traffic history to defend, and without legacy commitments — so the buyer keeps every option open.

Attribute	Detail
Domain	`drugtest.co` — exact-match for "drug test" (one of the most-searched health-information queries in the U.S.) on the premium .co TLD^[1]
Content library	90+ static pages including 5 test-type hubs, 4 panel pages, 10 detection-window pages, 9 substance profiles, 24 glossary entries, 4 long-form guides, 5 workplace pages, 4 at-home pages, 2 comparison pages, plus editorial, legal & author pages
Editorial standard	All content sourced from primary references (SAMHSA Mandatory Guidelines, U.S. DOT 49 CFR Part 40, ASAM, FDA) and medically reviewed by an AAMRO-certified MRO^[2]
Tech stack	Astro v5.18 static-site build, WCAG 2.2 AA accessibility, full Schema.org JSON-LD, OpenGraph, Twitter cards, llms.txt + llms-full.txt, sitemap, RSS
Brand position	Strict editorial rule: no "beat-the-test," synthetic urine, detox, or adulteration content. Differentiates from ~80% of the SERP in this category
Two interactive tools	"Find a Test" guided selector and "Detection Windows Explorer" filterable matrix (React-hydrated Astro islands)
Replacement cost	$71,320 (see methodology) — without domain. With domain: ~$80K–$96K.
Listing price	$24,500 USD — approx. 30% of replacement cost. Set to move; reasonable offers above $19,500 will be considered.
Why selling	Owner is focusing on a different vertical; this asset is brand-complete but operationally idle, so it is being offered to an operator who can put it to work.

Market opportunity

You are buying a footprint in a category that is doubling this decade.

Independent market research firms place the global drug-screening market between $9.42B and $10.36B in 2026, and project it to roughly double by 2030–2031 at a 15.5% compound annual growth rate. The growth is driven by federal expansion (the SAMHSA fentanyl panel addition took effect July 7, 2025), record-high workplace positivity, and the shift from urine-only to oral-fluid and at-home formats.

Global drug-screening market size, 2024–2031 (USD billions)

Conservative trajectory from blended Mordor Intelligence and MarketsandMarkets projections.^[3]

Bars: blended forecast. Dashed line: trend. Sources: Mordor Intelligence (2026), MarketsandMarkets (2024), Market Data Forecast (2024).

Regulatory tailwind

The federal panel just expanded — and content that explains it didn't exist a year ago.

On January 16, 2025, SAMHSA published updated Mandatory Guidelines authorizing fentanyl on the federal urine and oral-fluid panels (effective July 7, 2025).^[4] The DOT followed with a proposed rule under 49 CFR Part 40 to add fentanyl & norfentanyl to the DOT 5-panel.^[5] drugtest.co already has dedicated pages for the new federal panel and a fentanyl detection-window page — competitor sites are still describing the old 5-panel.

Demand signal

Workforce positivity is at a 25-year high — search interest follows.

Quest Diagnostics' annual Drug Testing Index reports the highest workforce positivity rate in 25 years, driven largely by cannabis.^[6] Every reported increase in positivity drives a downstream wave of search demand from employers writing policies, employees facing tests, and parents navigating the at-home category — exactly the audiences drugtest.co is built for.

Audience surface area

Five high-intent audiences, all addressable from one brand.

Audience	Approx. U.S. addressable	Commercial intent	Site hub
Employers & HR	~6.1M private employers	High — pre-employment, random, post-accident, MRO services	/workplace/
DOT-regulated drivers & safety-sensitive workers	~10M+ regulated workers^[7]	Very high — recurring testing, MRO disputes	/workplace/dot-vs-non-dot/
Parents & caregivers	~30M households w/ teens	Mid — at-home test kits ($15–$40 SKUs)	/at-home/
Healthcare & recovery	~21M adults w/ SUD	Mid — MAT clinics, telemedicine, labs	/guides/
Individuals (peace-of-mind)	Long tail	Variable — pre-employment, athletic, custody	/test-types/

What's included

Asset inventory — every page, every tool, every line of source

Acquisition is comprehensive: the domain registration, the full content library, the source code for the site, the brand identity, and all editorial infrastructure (style guide, source policies, MRO process documentation).

Asset category	Items	Count
Domain	drugtest.co — exact-match keyword, .co premium TLD, registered through transferable registrar	1
Test-type hubs	Urine · Saliva (oral fluid) · Hair · Blood · Breath/alcohol — each with detection windows, methodology, federal status	5
Panel reference pages	5-panel · 10-panel · 4-panel · DOT 5-panel (including July 2025 fentanyl update)	4
Detection-window pages	THC · Cocaine · Amphetamines · Opioids · Benzodiazepines · Barbiturates · PCP · Methadone · Fentanyl · Alcohol	10
Substance profiles	Educational, non-instructional profiles for all panel substances	9
Glossary entries	Chain-of-custody, immunoassay, GC-MS, LC-MS/MS, MRO, SAMHSA, cutoff, EtG, THC-COOH, benzoylecgonine, WADA, USADA, etc.	24
Long-form guides	Complete detection windows · 2026 employer compliance · False positives & cross-reactivity · Screening vs. confirmation (GC-MS/LC-MS/MS)	4
Workplace hub	DOT vs non-DOT · Building a testing program · MRO & confirmation · Cannabis & state law	5
At-home hub	How at-home tests work · Reading results · Talking to a teen	4
Comparison pages	5-panel vs 10-panel · Urine vs hair	2
Author profiles	Editorial Team · Meredith Okonkwo, MD, MRO · Jordan Park, JD · Rae Bennett, MSN, RN — each E-E-A-T-ready	4
Editorial & legal	About · Editorial policy · Medical disclaimer · Privacy · Terms · Affiliate disclosure · Contact	7
Interactive tools	"Find the right test" guided flow · "Detection Windows Explorer" filterable matrix	2
Discovery surfaces	sitemap-index.xml, sitemap-0.xml, robots.txt, rss.xml, llms.txt, llms-full.txt, site.webmanifest	7
Brand & design system	Wordmark, favicon, color tokens, type system (Fraunces / Hanken Grotesk / IBM Plex Mono), OG image template	—
Source & build	Full Astro source repository, build scripts, deployment-ready static output, Pagefind search index	—
Indexed editorial pages	Static, indexable, structured, schema-marked	90+

What you do not have to do.

You do not have to commission an editorial team. You do not have to find an AAMRO-certified MRO and contract medical review. You do not have to write 90 sourced pages. You do not have to design a brand, build a static site, write schema, or set up llms.txt. You do not have to negotiate for an exact-match keyword on a premium TLD. You start the day with everything assembled.

Valuation methodology

Three independent approaches, all converging above the asking price.

Because the site is sold without revenue history, the conventional 30–35× monthly profit multiple used for content sites does not apply.^[8] Instead, we triangulate on three asset-based methods that aggregators and brokers use for pre-revenue content properties.

A. Replacement cost

What it would cost to build this exact asset from a blank registrar at U.S. market rates for healthcare-content writers, an AAMRO-certified MRO reviewer, and a senior frontend engineer.

Component	Calculation	Cost (USD)
Editorial content (90 pages × avg. 1,400 words, fully sourced)	~360 hours @ $85/hr (specialized healthcare writer)	$30,600
Medical Review Officer (AAMRO) review & sign-off	~24 hours @ $300/hr (clinical MRO rate)	$7,200
Information architecture & UX design	~60 hours @ $120/hr	$7,200
Frontend build (Astro + a11y + Schema.org + dark mode)	~80 hours @ $110/hr	$8,800
Interactive tools (Find-a-Test + Detection Windows Explorer)	~40 hours @ $130/hr	$5,200
SEO setup, schema, OG, sitemap, llms.txt, robots	~16 hours @ $110/hr	$1,760
Brand identity (wordmark, type system, palette, OG template)	~12 hours @ $130/hr	$1,560
Editorial infrastructure (style guide, source policy, MRO process)	~16 hours @ $120/hr	$1,920
Author profiles & E-E-A-T documentation	~12 hours @ $90/hr	$1,080
Project management overhead (15%)	—	$9,798
Subtotal (build cost)		$75,118
Premium .co exact-match domain	Conservative midpoint of premium .co category-keyword sales	$9,000–$25,000
Replacement cost (low / high)		$84,118 – $100,118

Note: replacement cost assumes a single coordinated engagement at market rates. In practice, building this from scratch through a freelance marketplace or agency typically takes 9–14 months elapsed due to medical-review cycles — a delay that is not priced in above.

B. Asset-based market value

What each component would sell for on its own marketplace. Health-content aggregators benchmark medically-reviewed long-form at roughly $100–$200 per page; premium .co keyword domains regularly clear $5K–$25K at GoDaddy, Sedo, Dan, and Atom.^[9]

Asset	Low	High
drugtest.co — exact-match .co domain	$9,000	$25,000
Medically-reviewed health content (90+ pages @ $100–$200/pg)	$9,000	$18,000
Modern static-site build with Schema.org & a11y	$5,000	$12,000
Two interactive React-hydrated tools	$3,000	$6,000
Editorial framework & brand identity	$2,000	$5,000
Asset-based market range	$28,000	$66,000

C. Comparable domain sales context

Exact-match keyword domains anchor a well-documented market. Category .com leaders (Insurance.com $35.6M, CarInsurance.com $49.7M) demonstrate the ceiling.^[10] The .co counterparts trade at roughly 10–20% of the .com price for an equivalent keyword. drugtest.com itself is owned, operating commercially (HealthStreet's testing-services site) — the only path to the exact phrase on a premium TLD is the .co.

Reference sale / comp	Type	Price	Note
Insurance.com	Category EMD .com	$35.6M	Sale benchmark for top-of-category EMD
CarInsurance.com	Category EMD .com	$49.7M	Sale benchmark
Rocket.com	Brandable .com	$14.0M	Premium dictionary brand
Typical premium .co keyword domain	EMD .co	$5,000–$50,000	Industry midpoint for established TLD
Average premium .com aftermarket sale	Aftermarket .com	$2,000–$5,000	Per industry survey^[11]
drugtest.co (this listing)	EMD .co + 90-page content site	$24,500	Domain priced at midpoint; content effectively free

Three valuation methods vs. the asking price

The listing price sits below the low bound of every independent valuation approach.

The asking price falls below the low bound of replacement cost and asset-based valuation, inside the upper range of domain-only comps.

The math, in one sentence.

At $24,500, you are paying approximately 29% of conservative replacement cost, 37% of the high-end asset-based valuation, and the price of a mid-range premium .co domain alone — with the entire content library, build, and brand thrown in at no incremental cost.

Who this is for

Six operator profiles where drugtest.co immediately pays for itself.

Each profile below already exists, has marketing budget, and would either pay equivalent acquisition cost (CAC) for the equivalent search footprint, or pay more to a content agency for less. The brand-safe editorial position is the unfair advantage — drugtest.co is one of the few names in this category an enterprise-grade buyer can publicly own.

Profile 1

Workplace testing platform / B2B SaaS

HR-tech and compliance platforms (think TalentReef, iCIMS, or vertical players like Mintz Group, First Advantage, HireRight, Sterling) routinely pay $100–$300 CAC per qualified employer. A category-defining content brand is a leverage asset: it captures top-of-funnel demand and removes the gray-market trust tax.

Best fit · Marketing payback: 80–250 conversions

Profile 2

National lab or collection-site chain

Quest Diagnostics, LabCorp, Concentra, US Drug Test Centers and similar networks publish content that's frequently mistaken for promotional. An editorial brand on the exact-match domain solves the trust problem and rents fewer Google Ads on its own keyword. The "Find a Test" tool maps cleanly to a service locator.

Best fit · Lifts organic share of voice

Profile 3

At-home test kit brand (e-commerce / DTC)

Brands selling at-home kits via Amazon and Shopify (typical AOV $20–$80) face brutal CPC on "at home drug test" and "drug test kit." drugtest.co's /at-home/ hub, /panels/ pages, and "Reading results" guide are direct-fit conversion content. Affiliate revenue alone — at industry-standard 8–15% commission — can hit $3K–$8K/mo with modest traffic.

Best fit · Direct affiliate or owned-brand commerce

Profile 4

Telemedicine / occupational health provider

Telehealth networks offering MRO services, return-to-duty programs, or DOT-regulated services need credible top-of-funnel reach to employers and drivers. The /workplace/mro-and-confirmation/ and /workplace/dot-vs-non-dot/ hubs are pre-built lead-gen surfaces.

Best fit · B2B lead generation

Profile 5

Health publisher expanding reference verticals

Healthline, Verywell, GoodRx, Drugs.com and similar publishers acquire adjacencies to build a "definitive answer" footprint. drugtest.co fills a gap none of them currently own with deep, sourced topical depth — a single bolt-on rather than a 12-month editorial sprint.

Best fit · Vertical bolt-on for an existing publisher

Profile 6

Recovery / behavioral health network

Treatment networks, MAT programs, and recovery startups need brand-safe reach to families and individuals at the awareness stage. The /at-home/ "Talking to a teen" content and SAMHSA helpline integration map directly onto the funnel. No conflict with editorial stance.

Best fit · Awareness & referral

Technical & SEO foundation

Built to score, built to scale.

drugtest.co is engineered to be quoted by Google AI Overviews, Perplexity, ChatGPT, and Claude as much as it is ranked in classic SERPs. The stack is modern, the markup is dense with structured data, and the editorial provenance is machine-readable.

Astro v5.18 static buildPer-page hydration islands. Fast TTFB, zero unused JavaScript.
Schema.org JSON-LD on every pageOrganization, WebSite, BreadcrumbList, MedicalWebPage, Article, FAQPage, Person.
WCAG 2.2 AA accessibilitySkip-link, semantic landmarks, color-contrast verified, keyboard navigation.
llms.txt + llms-full.txtCurated and concatenated content surfaces for LLM/AI citation.
OpenGraph + Twitter cardsConfigured globally; OG image template ready for buyer rebrand.
Editorial provenance markupBylines, medical reviewer, dateModified, hasCredential, reviewedBy.
Cookieless by defaultNo third-party trackers. GDPR/CCPA friendly out of the box.
Pagefind static searchBuilt into the deployment; no external dependency.
WOFF2 self-hosted fontsFraunces, Hanken Grotesk, IBM Plex Mono — preloaded for speed.
Dark / light themesPre-paint theme bootstrapping. No FOUC.
Sitemap + RSS feedSitemap-index, sitemap-0.xml, rss.xml — all auto-generated at build.
Author E-E-A-T pagesFour named contributors including AAMRO-certified MRO.

The AI-Overviews/LLM citation thesis.

Drug testing is a high-stakes information category where Google AI Overviews are conservative, preferring sourced, medically-reviewed pages. Most domains ranking for "drug test" keywords today are either retailers (which AI assistants discount) or gray-market "how to pass" content (which assistants actively filter). drugtest.co is one of a small number of brand-safe, MRO-reviewed, primary-sourced properties in the category — exactly the kind of source AI Overviews and assistants are designed to surface. This is increasingly important as zero-click AI traffic grows.

Editorial moat

The brand-safe stance is the moat — and it's load-bearing.

Roughly 80% of the indexed SERP for high-volume drug-testing queries today is gray-market: synthetic urine retailers, detox-product affiliates, and "how to pass" content farms. drugtest.co is built on the opposite editorial rule, and the rule is the moat.

What drugtest.co publishes

Plain-language reference content for employers, parents, athletes, healthcare workers, and individuals
Detection windows tied to primary clinical and analytical sources
Regulatory explainers: SAMHSA Mandatory Guidelines, DOT 49 CFR Part 40, ASAM
Supportive at-home guidance, including SAMHSA Helpline integration
MRO-reviewed clinical content (false positives, cross-reactivity, screening vs. confirmation)

What drugtest.co will never publish

Synthetic / fake urine product reviews or recommendations
"Detox" or "flush" product affiliate content marketed to defeat tests
Dilution or adulteration technique guidance
"How to pass in 24 hours" / cheat content
Device tampering or temperature spoofing instructions

This editorial stance is documented in the public editorial policy and is the single biggest enterprise-buyer differentiator. It is the reason this property can be publicly owned by a national lab, an HR-tech platform, a publicly-traded telehealth provider, or a recovery network — categories where most existing "drug test" domains are unacquirable due to brand risk.

Growth playbook

Day-one monetization paths, ranked by speed-to-revenue.

A buyer with operational capacity can switch on revenue immediately. Below is a ranked sequence with order-of-magnitude estimates — illustrative only, not a forecast.

Strategy	Time to revenue	Order-of-magnitude	Why it's plausible
Affiliate program — at-home kits	2–4 weeks	$1K–$8K / mo	/at-home/ hub maps directly to Amazon Associates 1–4% or direct DTC 8–15% commissions on $20–$80 kits
Lead-gen for testing-services chains	4–8 weeks	$3K–$25K / mo	Drug-testing leads command $20–$120 each; "Find a Test" tool is a built-in lead-routing surface
B2B content sponsorship / branded hubs	6–12 weeks	$5K–$30K / mo	Compliance & HR-tech vendors sponsor employer-education content; /workplace/ hub is ready
Owned-brand integration	Immediate	Strategic value	If the buyer already sells testing services, use as top-of-funnel for own brand at zero CAC
MRO services / clinical-grade affiliate	3–6 months	$2K–$15K / mo	/workplace/mro-and-confirmation/ is a lead-gen surface for telehealth MRO networks
Programmatic display (Mediavine / Raptive)	6–12 months	$500–$4K / mo	Needs to clear ~50K sessions/mo thresholds first; high RPMs in health vertical ($18–$35)

Estimates above are based on publicly available industry benchmarks for health-information content sites (Mediavine RPM averages; affiliate program payout norms; healthcare lead-gen marketplace pricing). They are not a representation of past or guaranteed future drugtest.co performance — the site is being sold without revenue or traffic history.

Honest risk disclosure

What you should know before wiring funds.

A serious listing should be plain about what is and isn't being offered. Here it is.

No revenue, no historical traffic to defend

drugtest.co is sold as a pre-revenue brand asset. There is no MRR, no ad spend history, and no organic traffic baseline to "buy." The price reflects this — at 30% of replacement cost, you are buying the optionality, not a cash-flowing business. If you need a revenue-multiple comparable, this is not it.

SEO is a fresh slate

The site was launched in 2026 and is indexed, but it does not have an established ranking position for competitive keywords. Plan on 6–12 months of consistent operation before organic rankings materialize. The technical and editorial foundation is sound; the runway to rank still needs to be run.

Editorial constraints are non-negotiable for the brand

If a buyer's intent is to flip drugtest.co into a "how to pass" or synthetic-urine affiliate site, the brand position evaporates — and the public editorial policy will be archived on the Wayback Machine. The asset is defensible only as a brand-safe property. We will sell it to operators whose use case preserves that.

Medical reviewer continuity

Author bylines (Editorial Team, Meredith Okonkwo MD/MRO, Jordan Park JD, Rae Bennett MSN/RN) are part of the publication's E-E-A-T documentation. The buyer should plan to either retain medical review going forward, or update bylines to reflect their own reviewer. We can facilitate an introduction to the existing reviewer on closing.

Frequently asked

Acquisition FAQ

How is the transfer handled, and what protects the buyer?

Domain transfer goes through Escrow.com (or Dan.com / Sav.com escrow at buyer preference). Funds are released only after the domain transfer authcode is verified at the new registrar and the content/source repository is delivered. Standard escrow fees apply — typically 0.89% of transaction.

For the content and source code, we transfer a private GitHub repository (or zip archive) on the same release trigger. Both parties sign a one-page asset purchase agreement that names the assets and the transfer mechanism.

Can I see the source repository before paying?

Yes. After a basic introductory email (real identity / company), we share read-only access to the GitHub repository under a one-page mutual NDA. The entire compiled site is already publicly browsable at drugtest.co, so most due-diligence questions can be answered without touching source.

Why isn't there traffic data published on this page?

drugtest.co was launched in 2026 and is not being sold on a revenue or traffic multiple. There is no historical performance worth marketing — and we'd rather price the asset at replacement-cost / asset-based fair value than pretend a six-month-old site has a defensible traffic base.

If you do want to see current indexation and search-console data, we'll share a Google Search Console export with serious buyers under NDA.

Is the .com available, and does it compete?

drugtest.com is owned by HealthStreet (a testing services company). It does not target informational queries the way drugtest.co is built to — its content surface is shallow and service-oriented. For a buyer whose intent is to own the informational brand on the exact phrase, drugtest.co is the only path on a premium TLD.

.co is recognized by Google as a generic TLD with no ranking penalty vs. .com, and is the preferred TLD for tech-forward brands (Twitter used t.co; many YC startups launched on .co before migrating).

Can the asking price be financed or paid over time?

Yes, for qualified buyers. Standard structure: 60% on transfer via escrow, 40% over 90 days, secured by a UCC-1 on the domain. Add 4% for financing. Cash via escrow at $24,500 is preferred and is the default.

Are the authors / medical reviewer transferring with the site?

The author profile pages and bylines transfer as part of the content. Ongoing engagements with the individual contributors are separate and at the buyer's option — we can facilitate an introduction to the existing AAMRO-certified MRO on closing for buyers who want to retain medical review continuity (typical retainer is $2,000–$4,000 / month for a publication of this size).

What's the realistic timeline from accepted offer to handover?

Five to ten business days from accepted offer:

· Day 1–2: Sign one-page APA, fund escrow.
· Day 2–4: Initiate domain transfer with authcode at buyer's registrar.
· Day 3–7: Transfer GitHub repository and brand assets.
· Day 5–10: Domain transfer completes (registrar dependent); escrow releases.

Will you sign a non-compete in this niche?

Yes. The owner will sign a 24-month non-compete covering the U.S. drug-testing information niche (excluding any pre-existing healthcare or compliance properties, which will be enumerated). This is included at the asking price.

Is the price firm?

The list price is $24,500 USD. We will review reasonable offers above $19,500, and we have already declined offers below that threshold. The replacement-cost math above is the floor of the conversation.

Ready when you are

Acquire drugtest.co — the only brand-safe, exact-match informational property in a $9.86B category.

Reach out by email. Tell us briefly who you are and what you intend to do with the site — we ship a one-page acquisition memo and source-code access within 24 hours.

Buy now via Escrow.com → Learn about the site →

List price $24,500 USD · Escrow.com / Dan.com supported · Reasonable offers above $19,500 reviewed · 24-month non-compete included

References & sources

.co is recognized as a premium TLD for tech and startup brands; major exact-match domains sell across .com, .co, .ai, .io. Bluehost — Top Expensive Domain Sales 2026. PageWoo — How Much Do Domains Sell For (2026).
SAMHSA Mandatory Guidelines for Federal Workplace Drug Testing Programs and U.S. DOT 49 CFR Part 40 govern federally regulated workplace drug testing. drugtest.co cites both throughout. Federal Register — Mandatory Guidelines for Federal Workplace Drug Testing Programs (Jan 16, 2025).
Market size estimates for 2026 vary by methodology: Mordor Intelligence puts the drug-screening market at $9.86B in 2026, growing to ~$20.86B by 2031. MarketsandMarkets projects growth from $10.36B in 2025 to $21.29B by 2030 (CAGR 15.5%). Market Data Forecast estimates $9.42B in 2026. Yahoo Finance / Mordor Intelligence (April 2026). MarketsandMarkets — Drug Screening Market worth $21.29B by 2030.
SAMHSA's updated Mandatory Guidelines authorized fentanyl on the federal urine and oral-fluid panels, with effective date July 7, 2025. Federal Register, Jan 16, 2025.
DOT proposed adding fentanyl and norfentanyl to the 49 CFR Part 40 drug testing panel in 2025; final rule pending. Federal Register, Sep 2, 2025. Morgan Lewis — DOT proposes significant amendments to drug and alcohol testing (Oct 2025).
Quest Diagnostics Drug Testing Index reported workforce cannabis positivity at a 25-year high. CBS News — Record number of U.S. workers test positive for cannabis.
U.S. DOT regulates drug and alcohol testing for safety-sensitive transportation workers across FMCSA, FAA, FRA, FTA, PHMSA, and USCG. U.S. Department of Transportation, Office of Drug and Alcohol Policy and Compliance.
Content sites with revenue typically value at 30–35× monthly profit (~2.5–3× annual). This methodology is not used here because drugtest.co is being sold pre-revenue. The Website Flip — Valuing Non-Revenue Niche Sites. FE International — How to Value a Website or Internet Business.
Premium domain pricing tiers: $500 for brandable; $2K–$5K for typical aftermarket .com; $5K–$50K for category-keyword domains; $50K–$1M+ for high-traffic exact-match domains. Power Domaining — Premium Domain Names Guide.
Notable exact-match category sales include Insurance.com at $35.6M and CarInsurance.com at $49.7M, illustrating the ceiling value of category-defining EMDs. Bluehost — Top Expensive Domain Sales 2026.
Average premium .com aftermarket sales range $2,000–$5,000. PageWoo — Domain Sales 2026.
Workplace drug testing prevalence: ~56% of U.S. employers conduct testing; ~71% at worksites with 1,000+ employees. American Addiction Centers — Analysis of Employer Drug Testing.